Famotidine Patent Expiration
Famotidine was first introduced by Bausch Health Us Llc
Famotidine Patents
Given below is the list of patents protecting Famotidine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pepcid Ac |
US6814978 (Pediatric) | Process for preparing a soft tablet |
Feb 26, 2022
(Expired) | Kenvue Brands |
| Pepcid Ac | US6814978 | Process for preparing a soft tablet |
Aug 26, 2021
(Expired) | Kenvue Brands |
| Fluxid | US6024981 | Rapidly dissolving robust dosage form |
Apr 09, 2018
(Expired) | Ucb Inc |
| Fluxid | US6221392 | Rapidly dissolving robust dosage form |
Apr 09, 2018
(Expired) | Ucb Inc |
| Pepcid Ac |
US5854267 (Pediatric) | Method for preventing heartburn |
Jun 29, 2016
(Expired) | J And J Consumer Inc |
| Pepcid Ac |
US5854267 (Pediatric) | Method for preventing heartburn |
Jun 29, 2016
(Expired) | Kenvue Brands |
| Pepcid Ac | US5854267 | Method for preventing heartburn |
Dec 29, 2015
(Expired) | J And J Consumer Inc |
| Pepcid Ac | US5854267 | Method for preventing heartburn |
Dec 29, 2015
(Expired) | Kenvue Brands |
| Pepcid Ac |
US5667794 (Pediatric) | Heartburn treatment |
Nov 02, 2015
(Expired) | Kenvue Brands |
| Pepcid Ac | US5667794 | Heartburn treatment |
May 02, 2015
(Expired) | Kenvue Brands |
Famotidine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Famotidine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea | University of Cincinnati | NA |
WITHDRAWN
(Sep 1, 2026)
| PHASE3 |
| A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults | Pfizer | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Nuvation Bio Inc. | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE1 |
| Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19 | Northwell Health | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors | Epkin | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1 |
| A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants | Bristol-Myers Squibb | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |